Literature DB >> 22286760

Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1.

M-H Lee1, H Na, E-J Kim, H-W Lee, M-O Lee.   

Abstract

The metastasis-associated protein 1 (MTA1) is overexpressed in various human cancers and is closely connected with aggressive phenotypes; however, little is known about the transcriptional regulation of the MTA1 gene. This study identified the MTA1 gene as a target of p53-mediated transrepression. The MTA1 promoter contains two putative p53 response elements (p53REs), which were repressed by the p53-inducing drug 5-fluorouracil (5-FU). Notably, 5-FU treatment decreased MTA1 expression only in p53 wild-type cells. p53 and histone deacetylases 1/2 were recruited, and acetylation of H3K9 was decreased on the promoter region including the p53REs after 5-FU treatment. Proteomics analysis of the p53 repressor complex, which was pulled down by the MTA1 promoter, revealed that the poly(ADP-ribose) polymerase 1 (PARP-1) was part of the complex. Interestingly, p53 was poly(ADP-ribose)ylated by PARP-1, and the p53-mediated transrepression of the MTA1 gene required poly(ADP-ribose)ylation of p53. In summary, we report a novel function for poly(ADP-ribose)ylation of p53 in the gene-specific regulation of the transcriptional mode of p53 on the promoter of MTA1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286760     DOI: 10.1038/onc.2012.2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.

Authors:  E-B Choi; A-Y Yang; S C Kim; J Lee; J K Choi; C Choi; M-Y Kim
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

Review 2.  Structure, expression and functions of MTA genes.

Authors:  Rakesh Kumar; Rui-An Wang
Journal:  Gene       Date:  2016-02-09       Impact factor: 3.688

Review 3.  Medial Arterial Calcification: A Significant and Independent Contributor of Peripheral Artery Disease.

Authors:  Cynthia St Hilaire
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-01-27       Impact factor: 8.311

4.  NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis.

Authors:  Jiaqi Liu; Xianzun Tao; Yi Zhu; Chong Li; Kai Ruan; Zoraida Diaz-Perez; Priyamvada Rai; Hongbo Wang; R Grace Zhai
Journal:  Elife       Date:  2021-12-17       Impact factor: 8.140

5.  Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.

Authors:  Xiang Zhao; Dan Li; Dandan Huang; Huajie Song; Hong Mei; Erhu Fang; Xiaojing Wang; Feng Yang; Liduan Zheng; Kai Huang; Qiangsong Tong
Journal:  Mol Ther       Date:  2017-12-22       Impact factor: 11.454

6.  The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Authors:  Lu-Zhe Pan; Dae-Gyun Ahn; Tanveer Sharif; Derek Clements; Shashi A Gujar; Patrick W K Lee
Journal:  Cell Cycle       Date:  2014-02-07       Impact factor: 4.534

7.  EGCG suppresses Fused Toes Homolog protein through p53 in cervical cancer cells.

Authors:  Sridhar Muthusami; D S Prabakaran; Zhengzhe An; Jae-Ran Yu; Woo-Yoon Park
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

Review 8.  Transcriptional roles of PARP1 in cancer.

Authors:  Matthew J Schiewer; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2014-06-10       Impact factor: 5.852

9.  Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma.

Authors:  T-Y Na; N-L Ka; H Rhee; D Kyeong; M-H Kim; J K Seong; Y N Park; M-O Lee
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

10.  FOXP3 Inhibits the Metastasis of Breast Cancer by Downregulating the Expression of MTA1.

Authors:  Chenlin Liu; Jun Han; Xiaoju Li; Tonglie Huang; Yuan Gao; Baolong Wang; Kuo Zhang; Shuning Wang; Wangqian Zhang; Weina Li; Qiang Hao; Meng Li; Yingqi Zhang; Cun Zhang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.